The ATEMPT trial (NCT01853748) showed that in patients with HER2-positive stage I breast cancer, one year of adjuvant T-DM1 significantly improved 3-year iDFS compared to the wTH regimen. The gene discussed is ERBB2; the disease is breast carcinoma.